Table 3. Risk of stroke recurrence within 90 days for clopidogrel-aspirin combined therapy compared with aspirin alone.
| Glucose metabolism status | Aspirin | Clopidogrel-aspirin | Model 1* | Model 2# | ||||||
| No. | Events, n (%) | No. | Events, n (%) | Adjusted HR (95% CI)* | p value | p value for interaction | Adjusted HR (95% CI)# |
p value |
p value for interaction | |
| Non-DM | 1066 | 91 (8.5) | 1062 | 60 (5.6) | 0.66 (0.47-0.91) | 0.01 | 0.24 | 0.65 (0.47-0.91) | 0.01 | 0.15 |
| PDDM | 308 | 48 (15.6) | 303 | 32 (10.6) | 0.66 (0.42-1.04) | 0.07 | 0.64 (0.40-1.01) | 0.05 | ||
| NDDM-RH | 116 | 21 (18.1) | 109 | 18 (16.5) | 0.90 (0.48-1.70) | 0.75 | 0.98 (0.49-1.95) | 0.96 | ||
| Stress hyperglycemia | 30 | 21 (70.0) | 32 | 8 (25.0) | 0.35 (0.15-0.79) | 0.01 | 0.28 (0.10-0.76) | 0.01 | ||
Abbreviations: non-DM, non-diabetes mellitus; PDDM, previously diagnosed diabetes mellitus; NDDM-RH, newly diagnosed diabetes mellitus-related hyperglycemia; hs-CRP: high-sensitive C-reactive protein. *adjusted for age and sex. #adjusted for age, sex, body mass index, hs-CRP, history of ischemic stroke, TIA, myocardial infarction, known atrial fibrillation or flutter, angina, valvular heart disease, hypertension and hypercholesterolemia, smoking status, NIHSS score on admission, qualifying events of minor stroke or TIA, randomized treatment of aspirin alone or clopidogrel plus aspirin, use of antihypertensive medications, and statin medications.